Signaling pathways
-
BA6325 BNT411Summary: BNT411 is a selective agonist that induces IFNa release in vivo and in vitro. -
BA6326 CU-CPD107Summary: CU-CPD107 is a potent selective agonist.
-
BA6327 MobocertinibSummary: An orally active and irreversible EGFR/HER2 inhibitor that potently inhibits EGFR exon 20 insertion mutations for non-small cell lung cancer -
BA6328 PyrotinibSummary: Pyrotinib (SHR-1258) is a potent and selective dual inhibitor.
-
BA6329 BLU-945Summary: BLU-945 is a potent, highly selective, reversible epidermal growth factor receptor tyrosine kinase inhibitor (TKIs) with oral activity.
-
BA6330 LazertinibSummary: A blood-brain barrier-permeable, third-generation EGFR tyrosine kinase inhibitor, also an ABCB1/ABCG2 inhibitor and TRPA1 activator, for non-small cell lung cancer -
BA6331 SunvozertinibSummary: Sunvozertinib (DZD9008) is a potent (EGFR, Her2, especially mutant) inhibitor. -
BA6332 TX1-85-1Summary: TX1-85-1 is an irreversible inhibitor.
-
BA6333 BI-4020Summary: BI-4020 is a fourth generation, orally active, non-covalent tyrosine kinase inhibitor.
-
BA6334 MavelertinibSummary: Mavelertinib is a selective, orally effective and irreversible tyrosine kinase inhibitor with values of 5, 4, 12 and 3 nM for Del, L858R and double mutant T790M/L858R and T790M/Del, respectively.